Vanguard Global Advisers
CAMP icon

Vanguard Global Advisers’s CAMP4 Therapeutics CAMP Stock Holding History

Vanguard Global Advisers’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.8K Hold
11,615
– – ﹤0.01% 3061
2026
Q1 		$51.2K Buy
+11,615
New +$55.1K ﹤0.01% 3009

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Global Advisers's CAMP Position: Q2 2026 in Review

Vanguard Global Advisers held its CAMP4 Therapeutics (CAMP) position steady in Q2 2026 at 11,615 shares worth $50.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3061.

Vanguard Global Advisers first reported a position in CAMP in Q1 2026 and has held it in 2 quarters since. The position peaked at $51.2K in Q1 2026. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Vanguard Global Advisers held 11,615 shares of CAMP4 Therapeutics worth $50.8K as of Q2 2026.
  • Vanguard Global Advisers left its CAMP4 Therapeutics share count unchanged in Q2 2026.
  • CAMP4 Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3061 holding.
  • Vanguard Global Advisers first reported a position in CAMP4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's CAMP4 Therapeutics position peaked at $51.2K in Q1 2026.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.